— Message to Potential Investors —
“Investment in biotech business has a very high return potential but also associated with a very high risk.” This has been well known within the investor community.
What about Aavocyte?
Your Excellent Investment Opportunity —— Aavocyte
Similar to other bio start-ups, Aavocyte has a very high-return potential. Aavocyte has completed most of R&D, collected the preclinical / clinical data, and established the manufacture protocol. That makes Aavocyte an excellent investment opportunity among biotech start-ups.
The core technology of Aavocyte is a state-of-the-art platform technology, which had been originally developed in US and then validated in clinical practice in China for more than a decade. Having such a technology significantly improved, Aavocyte shows its capability of incorporating its technology (patent pending) as indications for most types of cancers, especially for solid tumors.
The safety and efficacy of the products developed on this platform had been well verified by achieving positive outcomes in thousands of cancer cases. The chances of failure or diminished outcomes in the clinical practice in US will be very low.